Looking beyond the drug receptor for clues to drug effectiveness

August 26, 2008

DURHAM, N.C. - Antipsychotic drugs that are widely used to treat schizophrenia and other problems may not work as scientists have assumed, according to findings from Duke University Medical Center researchers that could lead to changes in how these drugs are developed and prescribed.

Scientists have known that all antipsychotic drugs target the D2 receptor inside cells. New tests developed at Duke reveal that the biochemical pathways linked to this receptor - the pathways along which the drugs deliver their therapeutic effects - may function differently than previously understood.

The Duke team developed specialized tests and studied two main pathways that stem from the receptor. The first is the G-protein-dependent signaling pathway, and the other is the beta arrestin pathway.

Most antipsychotic drugs in use today were developed to target the G-protein signaling that occurs at the receptor. Only recently, beta-arrestin, a protein known as an "off-switch" for G-protein receptors, has been shown to also play a role in directing other cellular activities.

The tests uncovered surprising results. "Our work showed that all nine antipsychotic drugs we examined uniformly and more potently block the beta-arrestin pathway downstream of the D2 dopamine receptor," said Bernard Masri, Ph.D., lead author and postdoctoral researcher in the Duke Department of Cell Biology.

The drugs, however, showed a variety of effects at the G-protein pathway. "Some activated it, some blocked the G side totally, some blocked it only 50 percent - the drugs had different profiles for the G-protein pathway," Masri said. "So with this new information, drug manufacturers would want to make sure new compounds for antipsychotic use block the beta-arrestin pathway."

There may be even more pathways not yet known to flow from the D2 receptor, he added, pointing up the difficulty of developing a drug with the greatest possible effectiveness and fewest side effects. To further complicate the situation, antipsychotic drugs also work on receptors other than the D2 receptor. The drugs are used mainly to treat schizophrenia, which affects about 1 percent of people in the United States.

G-protein coupled receptors have been the most common target of such therapeutic drugs. The findings about beta arrestin's dual role open possibilities for developing new drugs. The importance of this concept for G-protein coupled receptors, especially the dopamine receptor, was demonstrated at Duke by the acclaimed receptor pioneer Robert J. Lefkowitz, M.D., and Marc G. Caron, Ph.D., the senior author on the current study.

"This work with antipsychotic drugs represents an entirely new approach for studying drug effects and developing new ones," Masri said of the Duke team's research, published the week of Aug. 25-29 in the Proceedings of the National Academy of Sciences.

In this study, the scientists used a technique called bioluminescence resonance energy transfer (BRET) in cells in culture. "Using cells to monitor specific receptor signaling pathways could provide more selective medicines with fewer side effects," said co-author Ali Salahpour, Ph.D., also a postdoctoral researcher in cell biology. "This is where pharmaceutical research is headed."

BRET is a luminescence-based technique that monitors interactions between molecules. One assay in this study followed the variation of cyclic adenosine monophosphate to look at the G-protein dependent pathway, and the other measured the direct interaction of beta arrestin with the dopamine D2 receptor. The antipsychotics were tested with both assays to look at which pathway(s) they were activating or blocking, and with what strength and efficacy.

Marc Caron, Ph.D., James B. Duke Professor in the Department of Cell Biology and director of the research laboratory, said, "Using these assays as a means to develop antipsychotics should be a useful way to target precise responses and improve patient symptoms." Unwanted side-effects, such as spasms or movement problems that cause the whole body or parts of the body to move uncontrollably, are associated with some of the antipsychotic drugs studied.

"Not all drugs used for schizophrenia have the same degree of movement-related side effects," Caron said. "For some of the drugs, these side effects may stem from interactions on the G protein part of the pathways." Therefore, evaluating antipsychotic drugs early that act less or not at all on the G side, but are effective on the beta arrestin side, could provide improved efficacy with many fewer side effects.

The next project for the scientists is to study these drugs and the relevant pathways in both normal mice and mice with traits of psychosis.

Duke University Medical Center

---

---

	Antipsychotics and Mood Stabilizers: Stahl's Essential Psychopharmacology, 3rd edition (Essential Psychopharmacology Series) by Stephen M. Stahl (Author) Relying upon the best-selling third edition of Stahl's Essential Psychopharmacology, Dr. Stephen M. Stahl has revised chapters covering antipsychotics and mood stabilizers for this third edition of Antipsychotics and Mood Stabilizers. More than one-third longer than the previous edition, Antipsychotics and Mood Stabilizers is essential reading for professionals treating psychosis and students learning the mechanisms of drug reactions. This updated edition includes advances in neurobiology and recent clinical developments to explain the concepts underlying drug treatment of psychiatric disorders. The fully revised text is complemented by many new illustrations and enhanced to reflect new knowledge and topics not covered in the previous edition. Intended as a primer text covering all...
	THE PROMISE OF ATYPICAL ANTIPSYCHOTICS: Fewer side effects mean enhanced compliance and improved functioning First-line second-generation drugs are approved ... new formulations. (Postgraduate Medicine) by JTE Multimedia Five new antipsychotic drugs introduced in the United States in the last decade offer physicians the ability to treat patients with schizophrenia and bipolar mania without the adverse effects of the first-generation antipsychotics. In this article, the authors discuss the advantages and side effects of these agents and present a guide to help physicians choose the optimal drug in the most favorable formulation for each patient. Citrome L, Volavka J. The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning. Original Publication Date: October 2004
	Antipsychotic long-acting injections by Peter Haddad (Author), Tim Lambert (Author), John Lauriello (Author) Antipsychotic long-acting injections (LAIs) were introduced in the 1960s to improve treatment adherence in schizophrenia. Subsequently, first-generation antipsychotic LAIs became widely used in many countries. Recently there has been a resurgence of interest in LAIs that partly reflects the introduction of several second-generation antipsychotic LAIs. This book brings together clinical and research findings on LAIs in a comprehensive volume, with chapters being written by international experts. Though the book concentrates on the use of LAIs in schizophrenia, the emerging evidence base for the use of LAIs in bipolar disorder is also discussed. A repeated theme throughout the book is the importance of prescribing decisions - whether for oral medication or an LAI, reflecting a...
	Safety of Antipsychotics.: An article from: Family Practice News by Lee Cohen (Author) This digital document is an article from Family Practice News, published by International Medical News Group on May 15, 2001. The length of the article is 709 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Safety of Antipsychotics. Author: Lee Cohen Publication: Family Practice News (Magazine/Journal) Date: May 15, 2001 Publisher: International Medical News Group Volume: 31 Issue: 10 Page: 27 Distributed by Thomson...
	LC-MS in Drug Bioanalysis by Q. Alan Xu (Editor), Timothy L. Madden (Editor) Clinical pharmacology plays an important role in today’s medicine. Due to the high sensitivity, selectivity, and affordability of a mass spectrometer (MS), the high performance liquid chromatography – mass spectrometry (LC-MS) analytical technique is widely used in the determination of drugs in human biological matrixes for clinical pharmacology. Specifically, LC-MS is used to analyze: anticancer drugs antidementia drugs antidepressant drugs antiepileptic drugs antifundal drug antimicrobial drugs antipsychotic drugs antiretroviral drugs anxiolytic/hypnotic drugs cardiac drugs drugs for addiction immunosuppressant drugs mood stabilizer drugs This book will primarily cover the various methods of validation for LC-MS techniques and applications used in modern clinical pharmacology.
	Essential Psychopharmacology of Antipsychotics and Mood Stabilizers (Essential Psychopharmacology Series) by Stephen M. Stahl (Author), Nancy Munter (Illustrator)
	Drug Induced Movement Disorders by Stewart Factor (Editor), Anthony Lang (Editor), William Weiner (Editor) An invaluable addition to the library of any neurologist, this book updates and presents the current state of the art clinical approaches to this subject, assisting neurologists and physicians alike in this difficult but increasingly common situation.
	Antipsychotics and their Side Effects (Cambridge Medicine) by David M. Gardner (Author), Michael D. Teehan (Author), Ross Baldessarini (Foreword) With the remarkable expansion in the use of antipsychotics, concerns about their immediate, intermediate, and long-term adverse effects have intensified. Despite this, studies consistently show that monitoring of patients taking antipsychotics can be inadequate, haphazard, or worse. This book provides a comprehensive review of the adverse effects of this pharmacologically complex therapeutic class, covering all commonly used conventional and atypical agents. In the first section, each chapter provides background information about an adverse effect, reviews the evidence linking the effect to various antipsychotics, and provides specific detection and monitoring recommendations. The second section provides unique monitoring guides for each antipsychotic. The third section provides the...
	A Guide to the Extrapyramidal Side Effects of Antipsychotic Drugs by D. G. Cunningham Owens (Author) Antipsychotic drugs have revolutionized the management of major psychiatric disorders and the outcomes of those who suffer from them. However, they often contribute to a range of adverse effects, among the most frequent and distressing of which are those resulting in disturbance of voluntary motor function. Extrapyramidal side effects--or EPS--are still poorly recognized and frequently misattributed. Despite vast research literature, there have been few attempts to bring together both the descriptive clinical elements of these disorders and major research conclusions pertinent to routine practice. This very readable and well-illustrated book seeks to rectify this problem in the hope of increasing clinicians' awareness of the issues and acknowledgement of their impact. This is a task made...
	Clinical handbook of antipsychotic drug therapy by Aaron S Mason (Author)